Database : MEDLINE
Search on : Psoriasis [Words]
References found : 42121 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 4213 go to page                         

  1 / 42121 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29524784
[Au] Autor:George Y; Aldeen M; Garnavi R
[Ad] Address:Department of Electric and Electronic Engineering, University of Melbourne, VIC, Australia. Electronic address: ygeorge@student.unimelb.edu.au.
[Ti] Title:Psoriasis image representation using patch-based dictionary learning for erythema severity scoring.
[So] Source:Comput Med Imaging Graph;66:44-55, 2018 Feb 23.
[Is] ISSN:1879-0771
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Psoriasis is a chronic skin disease which can be life-threatening. Accurate severity scoring helps dermatologists to decide on the treatment. In this paper, we present a semi-supervised computer-aided system for automatic erythema severity scoring in psoriasis images. Firstly, the unsupervised stage includes a novel image representation method. We construct a dictionary, which is then used in the sparse representation for local feature extraction. To acquire the final image representation vector, an aggregation method is exploited over the local features. Secondly, the supervised phase is where various multi-class machine learning (ML) classifiers are trained for erythema severity scoring. Finally, we compare the proposed system with two popular unsupervised feature extractor methods, namely: bag of visual words model (BoVWs) and AlexNet pretrained model. Root mean square error (RMSE) and F1 score are used as performance measures for the learned dictionaries and the trained ML models, respectively. A psoriasis image set consisting of 676 images, is used in this study. Experimental results demonstrate that the use of the proposed procedure can provide a setup where erythema scoring is accurate and consistent. Also, it is revealed that dictionaries with large number of atoms and small patch sizes yield the best representative erythema severity features. Further, random forest (RF) outperforms other classifiers with F1 score 0.71, followed by support vector machine (SVM) and boosting with 0.66 and 0.64 scores, respectively. Furthermore, the conducted comparative studies confirm the effectiveness of the proposed approach with improvement of 9% and 12% over BoVWs and AlexNet based features, respectively.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 42121 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29515113
[Au] Autor:Sullivan GP; Henry CM; Clancy DM; Mametnabiev T; Belotcerkovskaya E; Davidovich P; Sura-Trueba S; Garabadzhiu AV; Martin SJ
[Ad] Address:Molecular Cell Biology Laboratory, Department of Genetics, The Smurfit Institute, Trinity College, Dublin 2, Ireland.
[Ti] Title:Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases.
[So] Source:Cell Death Dis;9(3):378, 2018 Mar 07.
[Is] ISSN:2041-4889
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Sterile inflammation is initiated by molecules released from necrotic cells, called damage-associated molecular patterns (DAMPs). Members of the extended IL-1 cytokine family are important DAMPs, are typically only released through necrosis, and require limited proteolytic processing for activation. The IL-1 family cytokines, IL-36α, IL-36ß, and IL-36γ, are expressed as inactive precursors and have been implicated as key initiators of psoriatic-type skin inflammation. We have recently found that IL-36 family cytokines are proteolytically processed and activated by the neutrophil granule-derived proteases, elastase, and cathepsin G. Inhibitors of IL-36 processing may therefore have utility as anti-inflammatory agents through suppressing activation of the latter cytokines. We have identified peptide-based pseudosubstrates for cathepsin G and elastase, based on optimal substrate cleavage motifs, which can antagonize activation of all three IL-36 family cytokines by the latter proteases. Human psoriatic skin plaques displayed elevated IL-36ß processing activity that could be antagonized by peptide pseudosubstrates specific for cathepsin G. Thus, antagonists of neutrophil-derived proteases may have therapeutic potential for blocking activation of IL-36 family cytokines in inflammatory conditions such as psoriasis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1038/s41419-018-0385-4

  3 / 42121 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29507003
[Au] Autor:Lerman JB; Joshi AA; Bluemke DA; Mehta NN
[Ad] Address:National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD (J.B.L., A.A.J., N.N.M.).
[Ti] Title:Response by Lerman et al to Letters Regarding Article, "Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study".
[So] Source:Circulation;137(10):1092-1093, 2018 Mar 06.
[Is] ISSN:1524-4539
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1161/CIRCULATIONAHA.117.031675

  4 / 42121 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29501459
[Au] Autor:Gómez EC; Anguiano Igea S; Gómez Amoza JL; Otero Espinar FJ
[Ad] Address:Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Spain; Industrial Pharmacy Institute, University of Santiago de Compostela, Spain.
[Ti] Title:Evaluation of the promoting effect of soluble cyclodextrins in drug nail penetration.
[So] Source:Eur J Pharm Sci;117:270-278, 2018 Mar 06.
[Is] ISSN:1879-0720
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Soluble derivatives of ß-cyclodextrin (CD) have a high capacity to solubilise hydrophobic molecules and to interact with proteins and membrane component. As consequence CD derivatives shows a significant activity as drug absorption enhancers through different delivery routes, such as the oral, nasal, ocular or topical route. In this paper, the effect of two CD derivatives -methyl-ß-cyclodextrin (MBCD) and hydroxypropyl-ß-cyclodextrin (HPB)- on the structure and permeability of the nail plate has been studied using the drug model ciclopirox olamine. Results shows that MBCD and HPB interacting with the nail plate components, modifying their microporous structure and swelling characteristics. The ability of the cyclodextrins to interact with aromatic amino acids and to stabilise and unfold protein structures could be the most likely mechanisms responsible of the nail microstructure modifications. Aditionally CD allows to increase the soluble dose of ciclopirox olamine in aqueous lacquers made with poloxamer and N-acetylcysteine via the formation of high solubility complexes with the drug. Finally the studies of diffusion and penetration obtained using bovine hoof model confirm the enhancing effect of the cyclodextrins on the penetration and accumulation of the drug in the nail structure. Results shows the great potential of the CD for the elaboration of aqueous based nail lacquers containing hidrofobic drugs.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  5 / 42121 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29428424
[Au] Autor:Simões ACL; de Souza Aarão TL; de Sousa JR; Prudente DL; de Castro YG; Maneschy RB; Fuzii HT; Quaresma JAS
[Ad] Address:Tropical Medicine Center, Federal do Para University, Belem, Brazil.
[Ti] Title:Parvovirus B19 and in situ immune response in eczema and psoriasis skin lesions of patients from the Brazilian Amazon region.
[So] Source:Microb Pathog;117:27-31, 2018 Feb 09.
[Is] ISSN:1096-1208
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Parvovirus B19 (PVB19) is a virus found in the skin that causes asymptomatic infections and can exist in the host for long periods to time. The virus induces a local inflammatory response and is associated with the development of arthritis and other autoimmunes diseases. Parvovirus B19 DNA was investigated by PCR in the skin of 20 patients with psoriasis and 20 patients with eczema. Additionally, immunohistochemistry was used to characterize the expression of cytokines in these lesions. The sociodemographic variables were similar in the two groups studied. Psoriasis vulgaris was the most common clinical type in men (50%) and women (80%) (p = 0.0106). Comorbidities were observed in most patients with psoriasis (75%), with an OR of 14 (p = 0.0068). Another important finding was the high prevalence (50%) of psychiatric disorders in patients with psoriasis (OR = 16, p = 0.0218). Only two patients (10%) with psoriasis were positive for PVB19. Comparison of cytokine expression showed the same cytokine profile in the two groups (p > 0.05). However, expression of TNF-α tended to be higher in psoriasis patients. There was no significant positivity for PVB19 in the two groups studied. Immunohistochemistry showed higher expression of TNF-α in psoriasis lesions compared to the eczema group.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  6 / 42121 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29410110
[Au] Autor:Poh S; Chelvam V; Ayala-López W; Putt KS; Low PS
[Ad] Address:College of Engineering and Science - Chemistry, Louisiana Tech University, Ruston, LA.
[Ti] Title:Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases.
[So] Source:Nanomedicine;14(3):1033-1043, 2018 Feb 01.
[Is] ISSN:1549-9642
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Activated macrophages play a key role in the development and maintenance of inflammatory diseases such as atherosclerosis, lupus, psoriasis, rheumatoid arthritis, ulcerative colitis, and many others. These activated macrophages, but not resting or quiescent macrophages highly up-regulate folate receptor beta (FR-ß). This differential expression of FR-ß provides a mechanism to selectively deliver imaging and therapeutic agents utilizing folate as a targeting molecule. In an effort to determine whether inflammatory diseases can be targeted utilizing a folate-linked nanosize carrier, a PEG-coated liposome was prepared that incorporated a folate conjugated PEG that also could transport imaging or therapeutic cargo. We demonstrate that these folate-liposomes specifically bind to folate receptor positive cells and accumulate at sites of inflammation in mouse models of colitis and atherosclerosis. These two animal models show that folate-targeted liposomes could be successfully utilized to deliver fluorescent molecules and an anti-inflammatory drug (betamethasone) for diagnostic and therapeutic applications.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  7 / 42121 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524271
[Au] Autor:Griffiths CEM; Augustin M; Naldi L; Romiti R; Guevara-Sangines E; Howe T; Pietri G; Gilloteau I; Richardson C; Tian H; Jo SJ
[Ad] Address:Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
[Ti] Title:Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey.
[So] Source:J Eur Acad Dermatol Venereol;, 2018 Mar 10.
[Is] ISSN:1468-3083
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory disease, which often requires lifelong treatment. A strong partnership between the patient and healthcare practitioners should help to achieve effective treatment outcomes. OBJECTIVE: To assess concordance of views between psoriasis patients and their treating dermatologists relative to psoriasis severity, presence of symptoms and satisfaction with disease control achieved. METHODS: We used data from the Growth from Knowledge (GfK) Disease Atlas real-world evidence programme, a syndicated, retrospective, cross-sectional survey among dermatologists and their systemic therapy eligible psoriasis patients, conducted across 9 countries. Concordance was measured through patients and their dermatologist's identical answers to the same survey questions. Concordance was evaluated using percentage agreement between dermatologists and their patients, and Cohen's kappa (κ) statistic. The level of concordance was defined as "none" (κ≤0), "none to slight" (0.01-0.20), "fair" (0.21-0.40), "moderate" (0.41-0.60), "substantial" (0.61-0.80) and "almost perfect" (>0.8). The analysis was conducted for the overall population and for each participating country. RESULTS: Overall, 524 dermatologists and 3,821 psoriasis patients were included in the survey. Concordance of patient and dermatologist perceptions of psoriasis severity was fair both at diagnosis, and at the time of the survey (61% agreement, κ = 0.326 and 55% agreement, κ = 0.370, respectively). Higher levels of concordance were reported when patients assessed their psoriasis as moderate-to-severe (using Investigator's Global Assessment/Physician's Global Assessment [IGA/PGA] 5-point scale of 3 or 4). Concordance regarding symptoms ranged from fair to moderate (κ = 0.241-0.575). Satisfaction with psoriasis control was fair (39% agreement, κ = 0.213). Results showed different patterns of concordance across the participating countries although a low concordance was observed on the satisfaction with psoriasis control in all of them. CONCLUSION: Results from this multinational real-world survey indicate different perceptions between psoriasis patients and their dermatologist with respect to psoriasis severity, symptoms and disease control. This article is protected by copyright. All rights reserved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1111/jdv.14937

  8 / 42121 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524255
[Au] Autor:Gniadecki R; Leonardi CL; Gordon KB; Teixeira HD; Geng Z; Nader A; Gu Y
[Ad] Address:University of Alberta, Faculty of Medicine, Edmonton, AB, Canada.
[Ti] Title:Long-Term Optimization of Outcomes With Flexible Adalimumab Dosing in Patients With Moderate to Severe Plaque Psoriasis.
[So] Source:J Eur Acad Dermatol Venereol;, 2018 Mar 10.
[Is] ISSN:1468-3083
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may benefit from an increase in dosing frequency to 40 mg every week (EW). OBJECTIVE: To determine the long-term efficacy of adalimumab in patients with psoriasis with flexibility to escalate and de-escalate between EOW and EW dosing. METHODS: Data from an open-label study in patients with psoriasis who had received adalimumab in phase 2/3 studies and their extensions were included. Patients initially received 40 mg adalimumab EOW for 24 weeks. From weeks 24 to 252, patients whose Psoriasis Area and Severity Index response was <50% (PASI 50) could be dose-escalated to 40 mg EW and were re-evaluated at 6 and 12 weeks and then every 12 weeks thereafter. Patients who dose-escalated and achieved a PASI 75 response were de-escalated to EOW and could re-escalate to EW if response fell below PASI 50 again; no further de-escalation was allowed. Changes in PASI scores were reported at the last visit before dose escalation or de-escalation. RESULTS: By week 24, 64.1% of patients in the overall population (n=1256) achieved ≥PASI 75 response, 40.3% ≥PASI 90 response, and 21.7% PASI 100 response. Patients who had a
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1111/jdv.14926

  9 / 42121 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29524191
[Au] Autor:Nardin C; Colas M; Curie V; Pelletier F; Puzenat E; Aubin F
[Ad] Address:Service de Dermatologie, Centre Hospitalier Universitaire, Université de Franche Comté, Unité de recherche EA 3181, Besançon, France.
[Ti] Title:Pregnancy After Tubal Sterilization in a Woman Treated with Biologics for Severe Psoriasis.
[So] Source:Dermatol Ther (Heidelb);, 2018 Mar 09.
[Is] ISSN:2193-8210
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:Little is known about whether immunosuppressed patients mount the immunological response necessary to ensure tubal occlusion. Theoretical concern for non-occlusion has limited the use of hysteroscopic sterilization in patients on immunosuppressive therapies. The effects of tumor necrosis factor-alpha (TNF-α) blockers and interleukin (IL)-17 inhibitors on contraception and pregnancy for patients with psoriasis are poorly documented. We report a case of pregnancy that ended in miscarriage in a patient treated first with TNF-α and then with IL-17 inhibitors for severe psoriasis after tubal sterilization with micro-inserts. Our observation suggests that the efficacy of tubal sterilization by micro-inserts may be impaired by these two biologics and that the risk of miscarriage may be increased in women with psoriasis treated with secukinumab.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1007/s13555-018-0232-7

  10 / 42121 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29523578
[Au] Autor:Stafford N
[Ad] Address:Hamburg.
[Ti] Title:Dermatologists criticise Facebook and Instagram for removing psoriasis images.
[So] Source:BMJ;360:k1137, 2018 Mar 09.
[Is] ISSN:1756-1833
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Data-Review
[do] DOI:10.1136/bmj.k1137


page 1 of 4213 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information